Nantahala Capital Management LLC Invests $12.44 Million in Janux Therapeutics, Inc. $JANX

Nantahala Capital Management LLC acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 809,914 shares of the company’s stock, valued at approximately $12,440,279. Nantahala Capital Management LLC owned about 1.32% of Janux Therapeutics at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in JANX. AQR Capital Management LLC grew its stake in Janux Therapeutics by 71.7% in the first quarter. AQR Capital Management LLC now owns 9,717 shares of the company’s stock valued at $262,000 after purchasing an additional 4,059 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Janux Therapeutics by 18.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,403 shares of the company’s stock valued at $583,000 after buying an additional 3,393 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Janux Therapeutics by 12.5% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 186,394 shares of the company’s stock valued at $5,033,000 after buying an additional 20,657 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Janux Therapeutics by 82.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 247,424 shares of the company’s stock valued at $5,715,000 after buying an additional 112,116 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Janux Therapeutics by 12.0% in the 2nd quarter. Legal & General Group Plc now owns 47,353 shares of the company’s stock valued at $1,094,000 after buying an additional 5,055 shares in the last quarter. 75.39% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Monday, July 20th. Piper Sandler lowered their target price on shares of Janux Therapeutics from $30.00 to $26.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. TD Cowen upgraded shares of Janux Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Wolfe Research raised shares of Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 price target on the stock in a report on Monday. Finally, Evercore set a $22.00 target price on Janux Therapeutics in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Janux Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $36.46.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, insider Janeen Noel Doyle sold 4,059 shares of Janux Therapeutics stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $14.03, for a total transaction of $56,947.77. Following the completion of the sale, the insider directly owned 75,941 shares in the company, valued at approximately $1,065,452.23. The trade was a 5.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 7.90% of the company’s stock.

Janux Therapeutics Stock Performance

Shares of JANX stock opened at $18.03 on Friday. Janux Therapeutics, Inc. has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The firm has a market capitalization of $1.10 billion, a PE ratio of -10.99 and a beta of 2.50. The stock’s 50-day simple moving average is $16.12 and its 200-day simple moving average is $14.81.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, August 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million during the quarter, compared to analysts’ expectations of $19.07 million. Sell-side analysts forecast that Janux Therapeutics, Inc. will post -1.76 earnings per share for the current year.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.